A vaccine vector comprising a first polynucleotide encoding the antigenic polypeptide selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, or any combination thereof.

A vaccine vector comprising a first polynucleotide encoding the antigenic polypeptide selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, or any combination thereof.

A vaccine vector comprising a first polynucleotide encoding the antigenic polypeptide selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, or any combination thereof.

A vaccine delivery method is presented that includes a composition including as one component a slurry matrix that is a liquid at room temperature and a gel at physiological pH, physiological salt concentrations and/or physiological temperatures and as a second component one or more antigens. Also included are methods of inducing an immune response in a subject and vaccinating a subject by administering such compositions.

A vaccine delivery method is presented that includes a composition including as one component a slurry matrix that is a liquid at room temperature and a gel at physiological pH, physiological salt concentrations and/or physiological temperatures and as a second component one or more antigens. Also included are methods of inducing an immune response in a subject and vaccinating a subject by administering such compositions.

Vaccine vectors and methods of using the vaccine vectors to enhance the immune response to an Apicomplexan parasite and reduce the morbidity or mortality associated with subsequent infection are provided herein. The vaccine vectors include a polynucleotide encoding a Rhomboid polypeptide and optionally include an immune-stimulatory polypeptide suitably expressed on the surface of the vaccine vector.

Vaccine vectors and methods of using the vaccine vectors to enhance the immune response to an Apicomplexan parasite and reduce the morbidity or mortality associated with subsequent infection are provided herein. The vaccine vectors include a polynucleotide encoding a Rhomboid polypeptide and optionally include an immune-stimulatory polypeptide suitably expressed on the surface of the vaccine vector.

The present invention relates to an improved vaccine against Coccidiosis in poultry. The vaccine comprises live Eimeria oocysts in a composition with relatively high viscosity because of the inclusion of between 0.3 and 1.5% w/v Xanthan gum. Upon spray vaccination the new vaccine forms beads that are quickly ingested by the birds and which provide a rapid vaccine take, resulting in a quick and effective improvement of the signs of Coccidiosis upon challenge infection. Also the invention relates to a method for the heat sterilisation of a composition comprising Xanthan gum; by the inclusion of a concentration of a metal salt, an irreversible and dramatic reduction in viscosity can be largely prevented.

The present invention relates to an improved vaccine against Coccidiosis in poultry. The vaccine comprises live Eimeria oocysts in a composition with relatively high viscosity because of the inclusion of between 0.3 and 1.5% w/v Xanthan gum. Upon spray vaccination the new vaccine forms beads that are quickly ingested by the birds and which provide a rapid vaccine take, resulting in a quick and effective improvement of the signs of Coccidiosis upon challenge infection. Also the invention relates to a method for the heat sterilisation of a composition comprising Xanthan gum; by the inclusion of a concentration of a metal salt, an irreversible and dramatic reduction in viscosity can be largely prevented.

Vaccine compositions including a yeast comprising an immunostimulatory polypeptide and optionally an antigenic polypeptide are provided herein. The immunostimulatory polypeptide and the antigenic polypeptide are expressed or displayed on the surface of the yeast vaccine composition. Methods of using the vaccine composition to vaccinate subjects are also provided.